Article thumbnail

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

By Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen and Ulrik Lassen
Topics: Molecular Medicine, Angiotensin, Anti-angiogenic treatment, Antigen presentation, Glioblastoma, Immune activation, Predictive model, Vascular normalization
Publisher: 'Elsevier BV'
Year: 2016
DOI identifier: 10.1016/j.molonc.2016.05.005
OAI identifier: oai:pure.atira.dk:publications/ad8b762c-25e1-4a2a-a15b-44a754c47767

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.